APA (7th ed.) Citation

Pedrazzoli, A. A., Moreno, V., Gomez-Roca, C., Even, C., Cassier, P., Guerrero, T. H., . . . Calvo, E. (2020). 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment. Annals of Oncology, 31, S483. https://doi.org/10.1016/j.annonc.2020.08.674

Chicago Style (17th ed.) Citation

Pedrazzoli, A.B. Azaro, et al. "560P Safety and Efficacy of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins (IAPs), in Combination with Nivolumab in a Phase Ib/II Trial in Patients (pts) Failing Prior PD-1/PD-L1 Treatment." Annals of Oncology 31 (2020): S483. https://doi.org/10.1016/j.annonc.2020.08.674.

MLA (9th ed.) Citation

Pedrazzoli, A.B. Azaro, et al. "560P Safety and Efficacy of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins (IAPs), in Combination with Nivolumab in a Phase Ib/II Trial in Patients (pts) Failing Prior PD-1/PD-L1 Treatment." Annals of Oncology, vol. 31, 2020, p. S483, https://doi.org/10.1016/j.annonc.2020.08.674.